stoxline Quote Chart Rank Option Currency Glossary
  
Taysha Gene Therapies, Inc. (TSHA)
2.42  -0.01 (-0.41%)    05-01 16:00
Open: 2.44
High: 2.505
Volume: 1,403,587
  
Pre. Close: 2.43
Low: 2.35
Market Cap: 453(M)
Technical analysis
2024-05-01 4:49:14 PM
Short term     
Mid term     
Targets 6-month :  3.41 1-year :  3.97
Resists First :  2.92 Second :  3.4
Pivot price 2.52
Supports First :  2.14 Second :  1.78
MAs MA(5) :  2.39 MA(20) :  2.59
MA(100) :  2.13 MA(250) :  1.83
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  23.2 D(3) :  21.3
RSI RSI(14): 45.4
52-week High :  3.89 Low :  0.5
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ TSHA ] has closed above bottom band by 39.4%. Bollinger Bands are 10.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.51 - 2.52 2.52 - 2.54
Low: 2.32 - 2.33 2.33 - 2.35
Close: 2.4 - 2.42 2.42 - 2.44
Company Description

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Headline News

Tue, 30 Apr 2024
11 Analysts Assess Taysha Gene Therapies: What You Need To Know - Taysha Gene Therapies (NASDAQ:TSHA) - Benzinga

Sat, 27 Apr 2024
Another Biotech Steals The Show Following Major Clinical Data Release - The Globe and Mail

Thu, 25 Apr 2024
The Independent Director of Taysha Gene Therapies, Inc. (NASDAQ:TSHA), Paul Manning, Just Bought A Few More ... - Yahoo Movies Canada

Sat, 20 Apr 2024
Growth Investors: Industry Analysts Just Upgraded Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Revenue Forecasts By 23% - Simply Wall St

Sat, 20 Apr 2024
Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher - Yahoo Finance

Sun, 24 Mar 2024
News Flash: Analysts Just Made A Notable Upgrade To Their Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Forecasts - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 187 (M)
Shares Float 100 (M)
Held by Insiders 24.7 (%)
Held by Institutions 69.8 (%)
Shares Short 16,990 (K)
Shares Short P.Month 13,880 (K)
Stock Financials
EPS -0.96
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.4
Profit Margin 0 %
Operating Margin -438.4 %
Return on Assets (ttm) -29.9 %
Return on Equity (ttm) -294.1 %
Qtrly Rev. Growth 44 %
Gross Profit (p.s.) 0
Sales Per Share 0.08
EBITDA (p.s.) -0.38
Qtrly Earnings Growth 0 %
Operating Cash Flow -73 (M)
Levered Free Cash Flow -69 (M)
Stock Valuations
PE Ratio -2.53
PEG Ratio 0
Price to Book value 6.05
Price to Sales 29.29
Price to Cash Flow -6.2
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android